{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-090546","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2024-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.914710+00:00","generated_at":"2026-05-31T08:48:38.774435+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sagimet Biosciences enters into $75M ATM equity sales agreement with Cantor Fitzgerald","bullets":["Controlled Equity Offering Sales Agreement with Cantor Fitzgerald dated August 15, 2024.","Company may sell up to $75M of Series A common stock through at-the-market offerings.","Agent entitled to commission of up to 3% of gross proceeds from each sale.","Company has no obligation to sell shares and may suspend or terminate at any time.","Registration statement on Form S-3 filed same day; sales only after SEC declares effective."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-090546","json":"https://secwatch.observer/filing/0001104659-24-090546.json","markdown":"https://secwatch.observer/filing/0001104659-24-090546.md","text":"https://secwatch.observer/filing/0001104659-24-090546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924090546/0001104659-24-090546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924090546/tm2421627d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:48:38.774435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}